In March 2020, the U.S. Food and Drug Administration (FDA) recognized the need for more data to address the gaps in current research related to the safety of cannabidiol (CBD). Therefore, the FDA sought to collaborate with relevant stakeholders to gather data and address these gaps. Specifically, the FDA aimed to engage stakeholders to address gaps in research relating to acute and long-term outcomes related to male reproductive toxicity and liver toxicity; as well as, the impact of CBD on driving, interactions with alcohol, and dermal penetration.
On May 17, 2022, one study produced in response to the FDA’s 2020 request, released the results of its study, which demonstrated that consumption of CBD products “is not associated with elevated liver tests, low testosterone levels, or daytime drowsiness.” This study is an important step in filling the information gap surrounding CBD consumption and ensuring the FDA has all necessary information to develop the appropriate regulatory system needed to protect consumers. Read more about the study here.